Last year, sales of major antihistamines showed a clear recovery, exceeding the level it had made before the pandemic. Sales of antihistamines had plummeted in 2020 and 2021 during the COVID-19 pandemic. The analysis is that the increase in sales is likely due to the rise in allergy patients with the lifted mask mandates and the increase in outdoor activity that followed.

According to the market research institution IQIVA on the 21st, sales of the antihistamine Xyzal increased 18% YoY to reach KRW 14.4 billion the past year. Xyzal is a third-generation antihistamine developed by UCB Korea and is the leader in the antihistamine market.

Antihistamine drugs block histamine, which is involved i